OVERVIEW

Critical Insights on Recent Advances in Spinal Muscular Atrophy is organized by CME Outfitters, LLC.

Premiere Date: Tuesday, January 7, 2020
Credit Expiration Date: Thursday, January 7, 2021

This activity offers CE credit for:
•  Physicians (CME)
•  Nurses (CNE)
•  Pharmacists (ACPE)
•  ABIM (MOC)
•  Other

Credit Information:
CME Credit (Physicians):
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs).

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABP MOC Credit:
Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1.5 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Statement of Need:
Spinal muscular atrophy (SMA) is a leading, fatal, autosomal recessive disorder that affects approximately one in 10,000 live births. Nusinersen was approved as the first targeted therapy for SMA, and since its groundbreaking approval data has been published that demonstrates its efficacy for both infantile- and later-onset SMA populations. Additionally, recent guidelines were published that provide evidence-based recommendations for the diagnosis and management of SMA.

However, despite these advances there are knowledge gaps among health care providers (HCPs) regarding current data on safety and efficacy of approved and emerging therapies, which can result in treatment delays. Closing these gaps will promote early and accurate diagnosis and optimal treatment of patients with SMA.

In this CME Outfitters live and on demand webcast, expert faculty will host a case-based panel discussion that focuses on screening and early diagnosis of SMA and the importance of utilizing the latest clinical data on the efficacy and safety of approved and emerging therapies.

Learning Objectives:
At the end of this CE activity, participants should be able to:
• Review the pathophysiology and therapeutic targets of SMA.
• Apply the current recommendations for screening and early diagnosis of SMA.
• Evaluate the latest clinical data on the efficacy and safety of approved and emerging therapies for SMA.

The following learning objectives pertain only to those requesting CNE or CPE credit:
• Review the pathophysiology and therapeutic targets of SMA.
• Describe the current recommendations for screening and early diagnosis of SMA.
• Evaluate the latest clinical data on the efficacy and safety of approved and emerging therapies for SMA.